An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
Phase 1
- Conditions
- COVID-19Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- EUCTR2020-001366-11-LV
- Lead Sponsor
- World Health Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 100000
Inclusion Criteria
Consenting adults (age =18) hospitalised with definite COVID-19, not already receiving any of the study drugs, and without anticipated transfer within 72 hours to a non-study hospital.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10000
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 90000
Exclusion Criteria
Known allergy or contra-indications to any of study drugs (in the view of the physician responsible for their care).
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method